Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Multiple Myeloma: early-phase trial registry
167 of 441 indexed Multiple Myeloma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #11 of 28,707 conditions by registered trial count.
441 US clinical trials · 167 currently recruiting · #11 of 28,707 conditions by registered trial count
Multiple Myeloma: 441 US clinical trials tracked, 167 recruiting.
Multiple Myeloma is the subject of 441 registered US clinical trials on ClinicalTrials.gov, 167 of them currently open to new participants. 52 are in Phase 3-4 (later-stage) and 298 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 34 of these trials.
Enrollment posture brief
Registry condition multiple-myeloma
OPEN 167 | RECR 38% | LATE 52 | EARLY 298 | RANK #11 | SPON 34
Volume-matched condition peers
Nearest open-share peer: Multiple Sclerosis (38% recruiting · 317 trials)
Multiple Myeloma lists 167 open slots (38% of 441 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Multiple Myeloma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Multiple Myeloma recruits in line with its size-band peers.
167 of 441 indexed trials (37.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Multiple Myeloma trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 34 of 441 trials (7.7%). 154 distinct sponsors appear on at least one study for this condition label.
-
Typical Multiple Myeloma enrolment sits around 65 participants.
Median target enrolment is 65 among the 439 trials that report a genuine target (sentinel values excluded). 262 of those (59.7%) plan for fewer than 100 participants.
-
Multiple Myeloma research is mostly interventional.
386 interventional and 55 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
441 total, page 8 of 9
Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
Columbia University
NCT01731886
Randomized Study of Digital Life Coaching in Myeloma Patients Undergoing Transplantation
University of California, San Francisco
NCT04589286
Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma
Attaya Suvannasankha
NCT01142232
Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)
H. Lee Moffitt Cancer Center and Research Institute
NCT00617591
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
Jennifer Amengual
NCT01947140
Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)
National Heart, Lung, and Blood Institute (NHLBI)
NCT02440464
Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma
Hackensack Meridian Health
NCT01453101
Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant
University of Michigan Rogel Cancer Center
NCT00143845
An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.
Pfizer
NCT00555906
FM 140 vs FM100 Study in Patients With Multiple Myeloma
M.D. Anderson Cancer Center
NCT00505895
Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)
Washington University School of Medicine
NCT04682405
Longterm Follow-up of Subjects Treated With bb2121
Celgene
NCT02786511
Health-Related Quality of Life (QOL), Physical and Respiratory Function in Patients With Myeloma Affecting the Spine
University of California, San Francisco
NCT01006070
Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation
Memorial Sloan Kettering Cancer Center
NCT03276481
Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
Dana-Farber Cancer Institute
NCT02441686
Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy
Pack Health
NCT05064787
Bortezomib With Melphalan and Prednisone for Multiple Myeloma
Duke University
NCT00734149
Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation
University of Alabama at Birmingham
NCT01690143
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Bristol-Myers Squibb
NCT02252263
Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma
Seagen
NCT00079716
Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Memorial Sloan Kettering Cancer Center
NCT01351623
Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple Myeloma
M.D. Anderson Cancer Center
NCT00113841
T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer
Masonic Cancer Center, University of Minnesota
NCT00602693
A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma
AVEO Pharmaceuticals
NCT00725634
Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma
Oncotherapeutics
NCT01160484
Id-KLH Vaccine + T Cells in Subjects With Myeloma Undergoing Transplant
University of Pennsylvania
NCT01426828
Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT
University of Virginia
NCT04629430
Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H
Baylor College of Medicine
NCT00048412
Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma
Cephalon
NCT00920855
Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients
Genzyme, a Sanofi Company
NCT00322387
Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma
Geron Corporation
NCT00718601
Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors For The Treatment Of Multiple Myeloma
Stanford University
NCT00185653
A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma
Genentech
NCT01432353
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL
Masonic Cancer Center, University of Minnesota
NCT03019666
Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma
Barbara Ann Karmanos Cancer Institute
NCT00482846
Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ U
NCT00996957
Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT
University of California, San Francisco
NCT00516152
Dasatinib in Combination With Revlimid (and Dexamethasone)
Bristol-Myers Squibb
NCT00560391
A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure
Bristol-Myers Squibb
NCT05217082
Natural Killer Cells and Bortezomib to Treat Cancer
National Heart, Lung, and Blood Institute (NHLBI)
NCT00720785
Reduced Intensity Double Umbilical Cord Blood Transplantation
Massachusetts General Hospital
NCT01408563
Determining Normal Range for Free Light Chains in Serum Among Twins
University of California, San Francisco
NCT04191057
Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma
AEterna Zentaris
NCT00415064
Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)
Ajai Chari
NCT01651039
Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus
Massachusetts General Hospital
NCT00133367
Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma
University of Michigan Rogel Cancer Center
NCT02331368
Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma
Hackensack Meridian Health
NCT00784823
Ixazomib Rollover Study
Takeda
NCT02924272
Meloxicam vs Placebo for Mobilization
Massachusetts General Hospital
NCT02003625
A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse
Bristol-Myers Squibb
NCT00546780
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 156 |
| Phase 2 | 142 |
| Phase 3 | 45 |
| Phase 4 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Multiple Myeloma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Multiple Myeloma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Multiple Myeloma page
441 registered trials, 167 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 167 Multiple Myeloma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Multiple Myeloma trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Multiple Myeloma condition card totals 441 registered trials; most-linked intervention Dexamethasone; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.